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Objective: To compare the clinical efficacy and tolerance of didanosine (ddl) monotherapy with low-dose zidovudine/ 
didanosine (AZT/ddl) therapy among HIV-infected patients previously treated with AZT. 
Methods: A randomized controlled trial was carried out of ddl 400 mg  daily versus AZT/ddl 300/200 m g  daily among 
patients with CD4 cell counts s350 rnm3 and prior AZT treatment for a t  least 16 weeks. Fifty eight patients received ddl 
monotherapy and 66 combined treatment. 
Results: Patients were similar with respect t o  demographic, clinical and laboratory characteristics, and prior AZT 
treatment. Median duration of follow-up was 17.3 months. In the ddl group, 20 patients (34%) discontinued treatment 
because of toxicity, compared to 19 (29%) in the AZT/ddl group (p=0.38). There was no statistically significant difference 
in CD4 change between the two groups. In the ddl group, 16 patients (28%) developed a clinical endpoint (death or AIDS- 
defining opportunistic infection), compared to  33 (50%) in the combined therapy group (relative riskl.8; 95% confidence 
interval 1.1-2.9; p=O.OI) .  
Conclusions: For fairly advanced AZT-pretreated patients, monotherapy with ddl was clinically and statistically 
superior t o  the low-dose AZT/ddl combination in preventing AIDS-defining illness and death. When access t o  drugs is 
limited, e.g. in under-resourced countries, combining available drugs and reducing dosage may be less effective than 
a single drug at the conventional dosage. 
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INTRODUCTION clinical progression [2], and combined therapy is 
currently (1997) recommended as the initial treatment 
Long-term zidovudine (AZT) monotherapy is associ- of HIV infection [ 3 ] .  At the time this study was 
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AZT to didanoside (ddI) was logical, as AZT-resistant 
isolates remain susceptible to ddI [4]. It was not clear, 
however, whether continuing AZT with ddI in patients 
who had already received AZT for several months 
would be more beneficial than stopping AZT when 
ddI was started. In addition, available data suggested 
that higher doses of ddI were not providing a clinical 
advantage [5,6] and were associated with more side 
effects [6]. This randomized clinical trial was therefore 
designed to compare among HIV-infected patients 
previously treated with AZT the clinical efficacy and 
tolerance of two treatments options: ddI 400 mg alone, 
and low-dose combination therapy with AZT 300 mg 
plus ddI 200 mg. 
Regardless of the duration and the type of drugs 
previously received, drug dosage and compliance deter- 
mine treatment effectiveness. In the year 2000, 90% of 
the 30 million to 40 million HIV-infected persons will 
live in resource-poor countries [7] where drug access 
is often limited and cheaper treatment options with 
monotherapy or lower drug dosage are likely to be 
used even if not recommended. This study represents a 
careful controlled investigation of the potential impact 
of low drug dosage and poor compliance with mono- 
therapy. 
METHODS 
This was a multicenter, randomized, open label, con- 
trolled trial. Central block randomization (1 : 1) was 
organized to ensure an equal distribution of patients 
by treatment arm. Monotherapy patients received two 
ddI tablets of 100 mg twice daily (400 mg/day) and 
combined therapy patients one AZT tablet of 100 mg 
three times a day (300 mg/day) plus two ddI tablets 
of 50 mg twice-daily (200 mg/day). The mean (+ SE) 
dose of ddI was 6.3 ( L O .  1) mg/kg/day among patients 
in the ddI monotherapy arm and 3.1 (20.1) mg/kg/day 
in the combined therapy arm. 
Primary endpoints were new AIDS-defining events 
as in the 1993 European AIDS definition [8] and death. 
Other outcome measures were HIV p24 antigen (p24), 
CD4 cell counts and weight change. Measurement of 
viremia was not considered reliable or feasible at the 
time when this study was initiated. A toxicity end- 
point was reached when suspected toxicity led to 
dose reduction or drug withdrawal and was at least 
partly reversible after discontinuation of treatment. 
The following were considered severe adverse events: 
(1) hemoglobin <90 g/L or decrease of 30 g/L from 
baseline value; (2) neutrophils <750/mm3; (3) total 
serum or pancreatic amylase > 2  times upper normal 
limit (UNL); (4) creatinine kmase (CK) > 3  times 
UNL; (5) peripheral neuropathy (grade I1 or more); 
(6) other toxicity, grade 111 (severe) or grade IV (hfe- 
threatening). Adverse events were graded according to 
the recommendations of the American Clinical Trials 
Group. Intolerance was defined as the occurrence of 
side effects which did not quahfj as toxicity but resulted 
in definitive treatment interruption. 
AU participants except those recruited in Italy 
(three) were previously enrolled in the Swiss HIV 
Cohort Study (SHCS) [9]. The inclusion criteria were 
HIV infection, CD4 cell count (350/mm3, prior use 
of AZT (>300mg/day) for at least 16 weeks and 
Karnofsky score 280.  Patients were not eligible if 
the likelihood of their complying with the study was 
considered too poor by their physician, if they had a 
history of clinical pancreatitis or if they were <16 years 
of age. Patients were excluded if one of the following 
applied: hemoglobin < 90 g/L; neutrophils < 750/mm3; 
platelets <25 OOO/mm3;  alanine aminotransferase (ALT), 
and alkaline phosphatases >3 times UNL; creatinine 
>260 mmol/L; serum amylases >2 times UNL. 
Baseline laboratory values were measured <14 days 
prior to trial entry. The trial physician visited the centers 
twice a year to monitor the data-recording procedures 
and validate endpoints. The study was approved by the 
local ethics committee of each participating center. All 
participants gave written informed consent after reading 
a patient information sheet. 
To minimize the potential for introducing bias, 
all randomized patients were included in the com- 
parisons, irrespective of whether and how long they 
complied with their allocated regimen (intention-to- 
treat analysis). Statistical methods for univariate group 
comparisons included chi-square tests for proportion 
and t-tests for the continuous variables. The time to 
occurrence of first primary endpoints were compared 
in both arms using the log-rank test, Kaplan-Meier 
analysis and proportional hazards regression models. 
Baseline characteristics of patients 
Baseline characteristics of 124 eligible patients were 
similar in both groups and there were no statistically 
significant differences for any of the measured variables 
(age, gender, transmission category, CD4, weight, prior 
AZT, p24 antigen, AIDS diagnosis). However, patients 
randomized in the AZT/ddI arm had slightly lower 
CD4 cell count (144/mm3 versus 157/mm3), and a 
larger proportion were already diagnosed with AIDS 
(30% versus 22%). Eight patients were lost to follow- 
up or left the country without reaching a clinical or a 
toxicity endpoint (four in each group). The median 
follow-up was 17.3 months, similar in both groups (183 
person years of observation). 
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Toxicity and tolerance 
There were 12 toxicity endpoints in the monotherapy 
arm and 10 in the combined therapy arm. This 
difference was not statistically significant (NS). The 
most common side effects with both treatments were 
pancreatic and hematologic disturbances. In both 
groups, 14% of patients discontinued treatment because 
of intolerance. Intolerance was more common at the 
beginning of treatment (35% in the first month) whereas 
toxicity tended to appear after several months (39% 
after 1 year). Overall, 39 patients discontinued treat- 
ment, due to intolerance or toxicity. The average 
duration of treatment was 11 months, in both study 
arms. The median time to toxicity or intolerance was 
11.5 months with monotherapy and 9.9 months with 
AZT/ddI (NS, log-rank test). 
Efficacy endpoints 
The mean rate of CD4 cell count change (Table 1) was 
-2.0/mm3 per month of follow-up in the monotherapy 
arm and -1.5/mm3 in the combined therapy arm (NS). 
The evaluation of other hematologic variables, i.e. 
leukocytes, lymphocytes, hemoglobin and platelets, 
did not indicate a statistically significant advantage for 
either treatment. Weight loss was lower among rnono- 
therapy patients than combined therapy patients, and 
the weight difference between the groups was 2.1 kg 
@=0.03). 
There were less patients who developed an AIDS- 
defining event in the monotherapy group (15, 25.9%) 
than in the combined therapy group (27, 40.9%). This 
difference was not statistically significant (relative risk 
Table 1 Clinical endpoints by treatment group 
(RR) 1.6; 95% CI 0.9-2.7). The most common clinical 
events were candidosis and herpes zoster in the mono- 
therapy arm and candidosis, lymphoma and weight loss 
in the combined therapy arm. There were nine deaths 
among patients receiving ddI monotherapy (15.5%) and 
17 (25.8%) among those receiving combined therapy 
(RR 1.7; CI 0.8-3.4). In both groups, the main causes 
of deaths were respiratory (pneumonia), neurologic, 
lymphoma and Kaposi sarcoma. Considering death and 
clinical events together, the difference between the two 
treatment options was large and statistically significant: 
half the patients (33/66) receiving combined therapy 
died or experienced an AIDS-defining event compared 
to 27.6% (16/58) ofthose receiving monotherapy (RR 
1.8; CI 1.1-2.9;p=0.01). When the duration offollow- 
up was taken into account in a Cox proportional hazard 
analysis of AIDS-defining events or death (Figure l), 
the advantage provided by monotherapy was statistically 
significant (relative hazard (RH) 1.9; CI 1.1-3.5; 
p=0.03). This difference remained when CD4 cell 
counts were adjusted to take account of the slight im- 
balance between the two groups at the beginning of 
the study. After 6 months, 1 year and 2 years of follow- 
up, 96%, 78% and 64% of the patients still followed 
were alive and free of AIDS-defining events in the 
monotherapy group and 89%, 76% and 36% in the 
combined therapy group. ( p  (log rank)=0.03). The 
advantage provided by ddI monotherapy was consistent 
across all predetermined CD4 cell-count groups (<50 
CD4, 62% versus 69%; 50-150 CD4, 33% versus 70%; 
>150 CD4, 14% versus 27%). 
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Figure 1 Incidence of AIDS defining clinical events and death (Cox proportional hazard model). 
DISCUSSION 
Among patients with (350 CD4 cells/mm3 pretreated 
with AZT, the risk of death and AIDS-defining clinical 
events was 80% greater among those receiving com- 
bined therapy with low-dose AZT/ddI (300/200 mg 
daily) than among those receiving ddI monotherapy 
(400 mg daily). This difference was statistically signi- 
ficant and it was consistent in all CD4 groups. 
Data published after the initiation of this trial 
confirmed that, in AZT-pretreated patients, ddI alone 
is better than AZT [lo-131, especially among patients 
with >lo0 CD4 cells/mm3 [12]. Of four other trials 
comparing AZT with a ddI/AZT combination [3,5, 
14,151, two did not show an advantage in adding 
ddI to AZT compared to AZT alone among AZT- 
experienced patients. Combination therapy, however, 
was advantageous for those not previously exposed to 
AZT [3,14]. In the AIDS Clinical Trial Group (ACTG) 
175 trial [15], both ddI alone and AZT/ddI were better 
than AZT alone. In these trials [3,14,15] drug dosage 
was higher (AZT 600 mg daily, ddI 400 mg daily) 
than in the present trial. In the trial conducted by 
Collier et a1 [5], combination therapy provided a small 
advantage in terms of CD4 cell count and was less 
toxic. 
The superiority of ddI monotherapy over AZT/ 
ddI remains somewhat unexpected. It does not seem, 
however, to result &om a bias in favor of monotherapy 
patients. It is unlikely, for example, that the unblinded 
nature of the trial provided an artificial placebo- 
like advantage in favor of this group and there is no 
evidence of differential discontinuation, as the duration 
of treatment was identical in both groups. Patients in 
the two groups were comparable in almost all respects, 
although those receiving monotherapy had slightly 
more CD4 cells and less advanced disease. The differ- 
ences were small and not statistically significant, and 
the crude and the CD4-adjusted relative risks of death 
or AIDS-defining events were almost identical. Lastly, 
these results are quite similar to those of the Delta 2 
trial [3], where 46% of patients in the AZT/ddI arm 
experienced an AIDS-defining event or death com- 
pared with 50% in this trial. 
Because patients had received several months of 
monotherapy with AZT prior to randomization and 
were, in general, still receiving this drug, it is likely that 
many were harboring AZT-resistant viral strains. One 
can therefore postulate that the addition of low-dose 
ddI had little impact on viral replication and did not 
change the natural course of the disease. In comparison, 
switching to ddI 400 mg daily might have been more 
effective in decreasing viral load and slowing down 
disease progression. The dose of ddI prescribed in 
combination with AZT was almost as low as in the 
Alpha trial [6] (3.1 mg/kg/day versus 2.8 mg/kg/day). 
In that trial [6], ddI 200 mg daily was as effective as 750 
mg daily but patients were all intolerant to AZT and 
they had more advanced HIV disease than patients in 
this trial. Similarly, the difference between ddI alone 
and AZT/ddI in this trial was smallest among patients 
with advanced immunodeficiency. 
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The prescription of low-dose AZT/ddI to patients 
who had probably developed resistance to AZT was 
probably equivalent to low-dose ddI monotherapy. 
Switching from AZT to a higher dose of a single drug 
to which patients had not previously been exposed was 
more effective. This study dustrates the influence of 
adequate dose and prior drug antiretroviral treatment. 
Because poor compliance results in suboptimal dosage 
and is more likely with complex drug combinations 
[16], these results reinforce the importance of using 
simple drug protocols and helping the patients to 
adhere to prescribed regimens. Similarly, when both 
physicians and patients may be tempted to combine 
available drugs and reduce dosage (e.g. to decrease 
cost), such a strategy may be less effective than the 
provision of a single drug at the conventional dosage. 
Prior treatment, drug dosage and compliance critically 
influence outcome and may become the limiting 
factors in the use of the potent antiretroviral drugs 
which are now becoming available. 
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